Prostate-Cancer Mortality after PSA Screening

To the Editor: In their article, Schröder et al. (March 15 issue) 1 provide an update on the European Randomized Study of Screening for Prostate Cancer (ERSPC) after 11 years of follow-up. Their extended analysis is of great importance given the considerable controversy regarding the benefits, risks, and costs of population-based screening for prostate cancer, as reflected in the lively discussion that followed the release of the draft recommendation against screening by the U.S. Preventive Services Task Force. 2 It is an established principle of evidence-based medicine to base clinical decision making on the entire body of evidence rather than on individual . . .